PDUFA Priority Review (SPRO)
It was previously reported on May 3 that the Data Package may not be sufficient. Subjectively, that could result in an early dismissal from the FDA, a voluntary delay from the company, or the FDA could ask for an Advisory Committee Meeting. With the questions about the data looming, the runup period might not be […]